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Chimeric antigen receptor (CAR) T cells have shown 
great promise in the treatment of hematologic malig-
nancies but more variable results in the treatment of 
solid tumors and the persistence and expansion of CAR T 
cells within patients has been identified as a key correlate 
of antitumor efficacy. Lack of immunological “space”, 
functional exhaustion, and deletion have all been pro-
posed as mechanisms that hamper CAR T-cell persis-
tence. Here we describe the events following activation 
of third-generation CAR T cells specific for GD2. CAR 
T cells had highly potent immediate effector functions 
without evidence of functional exhaustion in vitro, 
although reduced cytokine production reversible by 
PD-1 blockade was observed after longer-term culture. 
Significant activation-induced cell death (AICD) of CAR 
T cells was observed after repeated antigen stimulation, 
and PD-1 blockade enhanced both CAR T-cell survival 
and promoted killing of PD-L1+ tumor cell lines. Finally, 
we assessed CAR T-cell persistence in patients enrolled 
in the CARPETS phase 1 clinical trial of GD2-specific 
CAR T cells in the treatment of metastatic melanoma. 
Together, these data suggest that deletion also occurs 
in vivo and that PD-1-targeted combination therapy 
approaches may be useful to augment CAR T-cell effi-
cacy and persistence in patients.
Received 16 December 2015; accepted 23 March 2016; advance online  
publication 19 April 2016. doi:10.1038/mt.2016.63
INTRODUCTION
Chimeric antigen receptor (CAR) T cells are a promising new 
technology in the field of cancer immunotherapy. Early clini-
cal data in patients with hematologic malignancies has been 
encouraging,1,2 however CAR T-cell treatment of patients with 
solid tumors has had limited success.3–5 More work is needed to 
optimize CAR T-cell therapy in general, and how best to ensure 
the antitumor efficacy of CAR T cells in solid tumor patients is less 
clear. For B-cell malignancies, a systematic review has identified 
preconditioning chemotherapy and CD19-specific CAR T-cell 
persistence as positively influencing progression-free survival.6 
In neuroblastoma patients receiving first-generation GD2-specific 
CAR T cells, better clinical outcomes were observed in those 
patients with CAR T cells detectable in blood beyond 6 weeks.4,7 
These findings indicate that CAR T-cell persistence is essential for 
positive patient outcomes.
Lack of CAR T-cell persistence has been attributed to several 
factors. In early clinical trials of CAIX-, CD19-, or CD20-specific 
CAR T cells, limited persistence postinfusion was observed, and 
suggested that immune-mediated deletion may have occurred.5,8,9 
Other groups have identified activation-induced cell death 
(AICD) resulting from IgG CH2CH3 region-derived spacer ele-
ments of the CAR binding the Fc-receptor on innate immune 
cells as a factor in lack of CAR T-cell persistence in preclinical 
models.10–12 AICD of tumor-specific T cells may also occur in the 
absence of Fc-receptor-engaging chimeric antigen receptors when 
T cells encounter cognate antigens.13,14 Although these processes 
are central to T-cell homeostasis, they may also limit CAR T-cell 
therapies that induce potent T-cell activation via multiple intra-
cellular signaling domains.15,16,17
Suppression or exhaustion of T cells can also contribute to 
failure of CAR T-cell expansion and persistence, and may partly 
be mediated by PD-1/PD-L1 interactions, which attenuate T-cell 
responses after antigen18–20 encounter.18–20 Preclinical studies in a 
Her2+ mouse tumor model have indicated that PD-1 is upregu-
lated on CAR T cells in vivo and can contribute to a lack of effi-
cacy.21 In one recent paper, exhaustion resulting from tonic CAR 
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signaling was identified in GD2-specific CAR T cells, although 
this may be specific to both the single chain variable fragment 
(scFv) in question (14g2a) and the intracellular signaling domains 
of the CAR, with CD28 promoting, and 41BB reducing, CAR 
T-cell exhaustion.22
Thus, the relative importance of factors that can limit CAR 
T-cell persistence remains unclear. Among these factors,  functional 
exhaustion and AICD have been identified in preclinical in vitro and 
in vivo models, and CAR-specific immune responses not perform-
ing prior lymphodeletion have been found to reduce CAR T-cell 
persistence in patients. Hence, we considered it important to fully 
define the effects of our third-generation CAR encoding CD3ζ, 
CD28, and OX40 on T-cell activation, viability, and function in 
vitro in order to identify factors that may influence CAR T-cell per-
sistence in patients. Importantly, our vector incorporates both the 
14g2a scFv and the problematic IgG CH2CH3 spacer identified by 
others as discussed above. Accordingly, we used samples obtained 
in preparation of and during the conduct of the CARPETS trial, 
a phase 1 clinical trial of third-generation GD2-specific, iCasp9-
expressing, autologous peripheral blood CAR T cells (GD2-iCAR-
PBT) in patients with metastatic melanoma, to better understand 
the events that occur during GD2-iCAR PBT activation.
Here, we show that GD2-iCAR T cells undergo rapid acti-
vation after antigen stimulation; demonstrate potent effector 
functions and only transient expression of markers of T-cell 
exhaustion. While we did not observe CAR tonic signaling lead-
ing to significant functional exhaustion, we did find clear evidence 
of reduced cytokine secretion and AICD after repeated stimula-
tion. In this report, we also aimed to identify practical ways of 
improving the effectiveness of CAR T cells and so we tested the 
recently approved melanoma therapeutic, pembrolizumab, an 
anti-PD-1 monoclonal antibody (mAb), for its ability to promote 
CAR T-cell survival and function. Importantly, PD-1 blockade 
was able to preserve cytokine secretion and prevent CAR T-cell 
AICD in vitro. We have also monitored CAR T-cell persistence 
and immune phenotype in four CARPETS trial patients. The data 
presented here offer a strong scientific rationale for an anti-PD-1/
CART-cell combination therapy approach in clinical trials of 
GD2-specific CAR T-cell therapy.
RESULTS
GD2-specific CAR T cells do not constitutively express 
PD-1 or LAG-3 and are not functionally exhausted
To understand what occurs to the GD2-iCAR T cells when they 
encounter antigen, we first analyzed markers of activation and 
exhaustion after stimulation in vitro. We tracked these markers 
during each step of the GD2-iCAR T-cell manufacturing process: 
initial activation of peripheral blood mononuclear cells (PBMC), 
retroviral transduction of the activated T cells with the vec-
tor SFG.iCasp9.2A.14g2a.CD28.OX40.ζ, subsequent expansion 
of the CAR T-cell product in IL-7 and IL-15.23 We also assessed 
marker expression after cryopreservation, and upon restimula-
tion of the thawed CAR T-cell product (Figure 1). GD2-iCAR T 
cells manufactured by this process had a predominately effector 
or effector memory phenotype, with smaller proportions of naive 
or central memory T cells.23 Further experiments described in 
this paper use patient-matched PBMC and nontransduced T cells 
(NT T cells) as controls. NT controls were subject to the same 
expansion conditions as CAR T cells and have a similar effector 
memory phenotype, whereas PBMC have been gradient-puri-
fied but are otherwise unmanipulated. We observed high levels 
of CD25, CD69, PD-1, and LAG3 expression during the initial 
activation, but only low levels of these markers on resting CAR 
T cells. CD25, CD69, PD-1, and LAG3 were upregulated again 
following restimulation of CAR T cells after cryopreservation, but 
to a lesser extent. Interestingly, direct restimulation of the CAR T 
cells via the CAR with the 1A7 anti-idiotypic antibody produced 
higher and more sustained levels of PD-1 expression on the cul-
tured T cells for Patients 101 and 102, compared to stimulation via 
CD3 and CD28 endogenous receptors (Figure 1d). This suggests 
that a more exhausted or less functional phenotype is induced 
by CAR signaling and although CAR T cells are not exhausted 
upon administration, they may become so after antigen encounter 
in vivo. Minimal TIM-3 expression was detected on CAR T cells 
during expansion or restimulation (data not shown).
The use of the term “exhausted” to describe T cells expressing 
markers such as PD-1 remains controversial and may instead rep-
resent T cells undergoing chronic antigen stimulation.24,25 A better 
measure of whether T cells are truly exhausted is their functional 
capacity after stimulation.18 CAR T cells demonstrate potent effec-
tor functions including cytokine secretion, particularly of IFNγ and 
TNFα, cytotoxic activity and proliferative functions following a 
3-day stimulation (Figure 2, see Supplementary Figure S2) and thus 
show no evidence of functional exhaustion. Others have reported 
decreased function of CAR T cells  following longer-term cultures 
and so we rested CAR T cells for 4 days and then stimulated for a fur-
ther 3 days with anti-CAR or anti-CD3/CD28 antibodies. On day 10, 
there were significantly reduced levels of IFNγ and TNFα, IL-6 and 
IL-10 production, and a complete loss of IL-2 production. Inclusion 
of pembrolizumab (anti-PD-1 mAb) in the repeated stimulation 
cultures was able to restore IFNγ and TNFα production, although 
IL-2 production was not rescued (Figure 2a–f). Reduced cytokine 
production  following repeated stimulation was also observed for NT 
control T cells, and thus was not an intrinsic function of CAR sig-
naling but rather a global effect resulting from long-term culture of 
T cells (see Supplementary Figure S2a). Cytotoxic T Lymphocyte 
(CTL) activity, on the other hand, was not significantly reduced after 
culture and restimulation, and the inclusion of anti-PD-1 mAb pro-
vided only modest enhancement (Figure 2g,h). Likewise, prolifera-
tion was not enhanced by PD-1 blockade (Supplementary Figure 
S2b,c). Thus GD2-iCAR T cells are not functionally exhausted, and 
do not become so after long-term culture and repeated stimulation. 
However, they do lose some of their functional capacity for multiple 
cytokine secretion suggestive of a more terminally differentiated 
phenotype, and PD-1 blockade partially restores this function.
Observations of long-term (>7 days) culture also revealed 
that GD2-iCAR T-cell proliferation required either exogenous 
cytokine or stimulation of CD3/CD28 or CAR and was not 
constitutive, as has been reported for other CAR constructs.26 
Following CAR-specific stimulation, the proportion of viable 
CAR-expressing cells decreased, the proportion of nonviable 
CAR-expressing cells increased and the remaining viable popula-
tion had lower levels of CAR expression as measured by 1A7-PE 
MFI (see Supplementary Figure S2d,e).
1136 www.moleculartherapy.org vol. 24 no. 6 jun. 2016
© The American Society of Gene & Cell Therapy
Activation-induced Cell Death in GD2-specific CAR T Cells
GD2-specific CAR T cells have basal levels of 
activation, and CAR engagement results in a rapid 
induction of downstream signaling events
To better understand the events following GD2-iCAR T-cell activa-
tion, we compared CAR T cells stimulated either by their CAR or 
CD3/CD28 molecules with NT controls and normal PBMC from the 
same patient (Figure 3 and Supplementary Figure S3). As reported 
previously,27 we observed distinct differences in the levels and timing 
of calcium flux, with flux occurring immediately after CAR engage-
ment without the requirement for cross linking (Figure 3a–c). We 
also found that CAR stimulation resulted in more rapid ERK phos-
phorylation, which was detectable at levels above unstimulated back-
ground by 6 hours in stimulated CAR T cells compared to 48 hours 
for stimulated NT controls or PBMC (Figure 3d,e). Stimulated CAR 
T cells were also more highly pERK+ when compared to stimulated 
controls. Likewise, AKT was also more rapidly phosphorylated in 
CAR T cells and pAKT was detectable at higher frequency in stimu-
lated CAR T cells compared to controls (Figure 3f,g). There were 
also higher basal levels of phosphorylation for these two signaling 
molecules in unstimulated CAR cells, which suggests some level of 
basal activation as identified by others.22 Conversely, peaks in phos-
phorylated Stat5 and 6 appeared at the same time after stimulation 
for CAR, NT controls, and PBMC although a greater percentage of 
CAR T cells were pStat6+ and a lower percentage were pStat5+, com-
pared to controls (Figure 3h,i). Finally, the active form of caspase 3 
was detected at 12 hours poststimulation for CAR T cells and NT 
controls, compared to 24 hours for PBMC (Figure 3j,k). Thus, the 
CD28, OX40 and CD3ζ domains of the third-generation CAR result 
in rapid activation and calcium flux of GD2-iCAR T cells without 
receptor cross-linking, and GD2-iCAR T cells have higher basal 
levels of activation that may make them more susceptible to AICD 
in vivo. Importantly, NT T-cell controls also displayed higher basal 
Figure 1  Markers of activation and exhaustion on GD2-iCAR and paired nontransduced T cells in vitro. Patient peripheral blood mononuclear 
cells were activated, transduced with GD2-iCAR retroviral vector and expanded for 14 days before cryopreservation. Chimeric antigen receptor (CAR) 
T cells and nontransduced (NT) T-cell controls were manufactured from four patients with metastatic melanoma. Cells were then thawed and restimu-
lated. (a) CD25 and CD69 expression during culture. (b) PD-1 expression during culture. (c) LAG-3 expression during culture. (d) Difference in PD-1 
expression after restimulation with 1A7 or -anti-CD3/CD28 antibodies. Representative data are shown for patient 101. All samples were analyzed in 
duplicate, with graphs displaying mean ± standard error of the mean. The gating strategy is shown in Supplementary Figure S1.
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levels of pAKT than PBMC controls, as well as a more rapid activa-
tion of caspase 3 poststimulation, which suggests that the activated 
phenotype is also due to the expansion culture conditions and not 
solely to CAR signaling. As previously noted, the culture conditions 
generate a majority of effector/effector memory T cells.23
GD2-specific CAR T cells undergo AICD after repeated 
antigen stimulation
Given that CAR engagement with an anti-idiotypic antibody-
induced marker of AICD, we wished to further explore the 
events following antigen encounter by CAR T cells, however 
Figure 2 Functional capacity of GD2-iCAR T cells in vitro with or without PD-1 blockade. Thawed chimeric antigen receptor (CAR) T cells were 
stimulated via CD3/CD28 or CAR in the absence of exogenous cytokine and in the absence (white) or presence (gray) of 20 µg/ml anti-PD-1 block-
ing antibody. Supernatants were collected after 3 days (day 3 plain bars) stimulation or 3 days after a restimulation on day 7 (Day 10, striped bars) 
and diluted 1/10 prior to analysis for cytokine secretion. (a) IFNγ. (b) TNFα. (c) IL-2. (d) IL-10. (e) IL-4. (f) IL-6. (g) CAR T-cell killing of GD2+ PD-L1- 
(M238, circles) and PD-L1 + (M238R, squares) melanoma cell lines ± 20 µg/ml anti-PD-1. Cells were thawed, rested overnight and then cultured 
with 51Cr-labeled tumor lines for 6 hours. (h) CAR T-cell killing of melanoma cell lines on day 7 after 3 days of stimulation. Cells were thawed, rested 
overnight and then stimulated with anti-CAR for 3 days and rested for 4 days before culture with 51Cr-labeled tumor lines for 6 hours. Flow samples 
were analyzed in duplicate and 51Cr assays in triplicate. Representative data are shown for patient 101, and graph display mean ± standard error of 
the mean. Cytokine secretion for nontransduced controls are shown in Supplementary Figure S2.
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Figure 3 Comparison of downstream signaling events following chimeric antigen receptor (CAR) or CD3/CD28 stimulation. Calcium flux 
after stimulation of thawed CAR T cells with primary (1°) antibodies specific for (a) the CAR (1A7) or (b) the CD3 (OKT3) receptors, with or without 
cross-linking by antimouse IgG secondary (2°) antibodies. (c) Ionomycin and isotype control and a secondary antibody were used as positive and 
negative controls, respectively. Anti-CD28 and anti-OX40 antibodies were also used in conjunction with anti-CD3 but did not induce markedly dif-
ferent calcium flux compared to anti-CD3 alone (data not shown). CAR T cells, nontransduced (NT) T cells and peripheral blood mononuclear cells 
(PBMC) were stimulated via CAR or CD3/CD28 receptors and analyzed for signaling molecule phosphorylation. (d) and (e) pERK+ T cells at 6 and 
48 hours. (f) and (g) pAKT+ T cells 12 and 24 hours. (h) pSTAT5+ T cells at 24 hours. (i) pSTAT6+ T cells at 12 hours. (j) and (k) active caspase 3 in T 
cells at 12 and 24 hours. CAR T cells and NT T cells and PBMC were tested in duplicate. Representative data are shown for patient 102, and graphs 
display mean ± standard error of the mean. The gating strategy is shown in Supplementary Figure S3.
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it is difficult to model complex tumor environments in vitro. 
Prolonged or repeative antigen “stress-test” models of repeated 
stimulation have been reported by others,22,28 and give results 
that better correlate with in vivo data. We performed this “stress-
test” assay with GD2-iCAR T cells from patients that were 
repeatedly passaged onto GD2+ melanoma (M238 or M238R) 
or GD2+ neuroblastoma (LAN-1) cells every 24 hours (Figure 4 
and Supplementary   Figure S4). At each transfer, the sur-
vival of the tumor cells was analyzed by Annexin V and DAPI 
(4′,6-Diamidino-2-Phenylindole, Dihydrochloride) staining, 
and a sample of the CAR T-cell population was also retained for 
analysis of viability and activation markers (CD25 and CD69).
Using this assay, we found that the percentage of viable GD2-
iCAR T cells decreased with each stimulation and this depended 
on the level of antigen expression because melanoma cell lines with 
lower GD2 expression (M238) induced lower levels of CAR T-cell 
death compared to the highly GD2+ LAN-1 cell line (Figure 4a,b). 
In order to identify potentially beneficial combination therapies, 
we then included the currently available antimelanoma therapy, 
pembrolizumab (anti-PD-1 mAb), in these cocultures to see 
whether it affected AICD. Anti-PD-1 mAb did not affect activa-
tion levels but was able to completely restore CAR T-cell viability 
to levels observed for CAR T cells cultured with GD2- cell lines 
on days 1 and 2, although by day 3 this effect lessened (Figure 4c 
Figure 4 Activation-induced cell death (AICD) after repeated antigen stimulation of GD2-iCAR T cells with GD2+ tumor cells. Thawed chimeric 
antigen receptor (CAR) T cells were passaged daily onto tumor cells, and cells were collected at days 1, 2, and 3 for analysis of activation (CD25 and 
CD69) and cell death (Annexin V and DAPI) by flow cytometry. SK-Mel cells provide a GD2- control and nontransduced (NT) T cells provided controls 
lacking CAR expression. Anti-PD-1was included in some cultures. CAR T-cell activation (a) and viability (b) after repeated stimulation with tumor cell 
lines. (c) CAR T-cell death after repeated stimulation by GD2hi neuroblastoma cell lines (LAN-1), with or without anti-PD-1. (d) CAR T-cell killing of 
GD2hi PD-L1- neuroblastoma cells (LAN-1), with or without anti-PD-1. (e) CART-cell killing of GD2+PD-L1+ melanoma cells (M238R), with or without 
anti-PD-1. Repetitive antigen stress-test assays were performed in duplicate. Representative data are shown for patient 101, and graphs display mean 
± standard error of the mean. The gating strategy is shown in Supplementary Figure S4.
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and Supplementary Figure S4c). PD-1 blockade also resulted 
in enhanced killing of the PD-L1+ melanoma cell line (M238R, 
Figure 4e), but not of the PD-L1- cell lines (LAN-1: Figure 4d, 
M238: Supplementary Figure S4d).
The third-generation CAR incorporates an inducible caspase 
9 suicide gene (iCasp9) and it is possible that this could contribute 
to the AICD observed. To investigate this possibility, we gener-
ated CAR T cells from the same patient PBMC using an earlier 
generation vector that encodes CD3ζ, CD28, and OX40 signal-
ing domains but not iCasp9. These cells were found to be equally 
susceptible to AICD cell death when repeatedly stimulated with 
GD2+ LAN-1 cells, 1A7 anti-idiotypic antibody or via CD3/CD28 
(Supplementary Figure S4e).
AICD is PD-1 dependent and can occur in the absence 
of tumor-derived PD-L1
In stimulation assays using plate-bound anti-CD3/CD28 or 
1A7 antibodies, PD-1 blockade enhanced cytokine production 
(Figure 2), and in stress-test assays, PD-1 blockade promoted the 
survival of CAR T cells after activation with the PD-L1- cell line 
LAN-1 (Figure 4). This result suggested that homo- or hetero-
typic interactions between PD-1-expressing T cells and T cells 
expressing PD-1 ligands such as PD-L1 might contribute to the 
observed AICD and suppression of T-cell function. Although 
PD-L1 expression on intratumoral lymphocytes has been recently 
reported,20 we have not found previous reports of PD-L1 expres-
sion on CAR T cells.
After stimulating the CAR T-cell product in vitro, we found 
that PD-L1 expression peaked at days 3–7 poststimulation 
(Figure  5a). Given that PD-L1+ T cells have been little charac-
terized in the literature, we analyzed the PD-L1+ CAR T cells for 
surface markers and function. We found that they had equiva-
lent levels of activation marker expression and higher levels of 
PD-L2 and FASL expression but demonstrated lower levels of 
proliferation and lower PD-1 and LAG-3 expression than PD-L1- 
CAR T cells (Figure 5b). A transient PD-L1 and PD-1 double-
positive population was observed on day 3 after stimulation, 
which accounted for 40% of the total GD2-iCAR PBT popula-
tion. Freshly isolated PBMC expressed PD-L1 primarily on non-
CD3+ cells, including CD14+ macrophages, and PD-L1 was not 
coexpressed with PD-1. However, when PBMC were activated 
with anti-CD3/CD28, ~40% of T cells were likewise found to 
coexpress PD-1 and PD-L1. We also noted that although PD-1 
was more highly expressed on the CD4+ subset before and after 
activation, its ligand, PD-L1, was expressed at equivalent levels 
before activation and more highly on the CD8+ subset after activa-
tion (Supplementary Figure S5a,b,d). Blockade of PD-L1 with a 
specific mAb inhibited AICD significantly on day 1 of coculture, 
but not on day 2 or day 3, and enhanced killing of the PD-L1+ 
M238R cell line, but not of the PD-L1- M238 and LAN-1 cell 
lines (Figure 5e–h). Blockade of PD-L2 had no significant effect 
on CAR T-cell viability. We also performed knockdown of either 
PD-1 or PD-L1 by siRNA, but only achieved a transient reduc-
tions in surface expression of 30–40%, however, there was a trend 
toward increased viability of CAR T-cells after PD-1 knockdown 
whereas PD-L1 knockdown significantly reduced CAR T-cell sur-
vival (data not shown). We hypothesize that these different effects 
relate to differences in PD-L1 forward and reverse signaling upon 
binding to PD-1,29,30 with reverse signaling in PD-L1+ CD8 T cells 
reportedly promoting survival.
Others have reported Fas Cell Surface Death Receptor and 
Ligand (FAS-FASL) interactions are critical for AICD of CAR T 
cells.10,15 We found that CAR T cells have constitutively high FAS 
expression, and upregulate intermediate levels of FASL after activa-
tion (see Supplementary Figure S5c). Blockade of FAS also resulted 
in reduced AICD as expected (see Supplementary Figure S5e). 
However, in some cases, when FAS-blocking antibody was added 
to the tumor cell coculture stress-test assay, tumor cells maintained 
higher viability (see Supplementary Figure S5f–h). Thus, blockade 
of FAS or PD-1 interactions between CAR T cells can promote their 
survival, but only PD-1 blockade was found to consistently preserve 
CAR T-cell cytotoxic function.
To isolate extrinsic signals provided by tumor cells during 
coculture from CAR T-cell-intrinsic signaling occurring after 
activation, we simulated repeated antigen engagement by cross-
linking CAR-bound 1A7 antibody with a secondary antimouse 
IgG antibody (Figure 6). This result confirmed that direct CAR 
engagement could induce AICD in the absence of tumor cells 
because the percentage of cells undergoing AICD significantly 
increased when the 1A7 antibody was cross-linked by a second-
ary antibody (Figure 6a,b). PD-L1 expression, but not PD-1 
 expression, was also significantly increased by cross-linking 
(Figure 6c,d). We found that blocking antibodies to both PD-1 
and PD-L1 prevented AICD after cross-linking (Figure 6e), in 
agreement with the findings from the tumor coculture stress-test 
assays. In particular, anti-PD-L1 restored CAR T-cell viability to 
the level of unstimulated cells.
GD2-specific CAR T cells demonstrate limited 
persistence in patients and upregulate PD-1 and  
PD-L1 after infusion
We have examined patient-derived CAR T cells stimulated in vitro 
but although these experiments have identified some important 
potential factors in CAR T-cell persistence and efficacy but we 
cannot fully recapitulate the complex environment that influ-
ences CAR T-cell persistence within patients. In the CARPETS 
study, we have the opportunity to observe the fate of CAR T cells 
administered to the first four patients enrolled in this trial. The 
first cohort of patients, 101 and 102, received single IV injec-
tions at dose level 1 of 1 × 107 CAR T cells/m2 in conjunction with 
dabrafenib therapy but with no prior lymphodepletion. After 
a protocol amendment, the second cohort of patients, 201 and 
203, received single IV injections at dose level 2 of 2 × 107 CAR 
T cells/m2. Patient 201 received lymphodepleting fludarabine and 
cyclophosphamide chemotherapy before the CAR T-cell infusion. 
Patient 203 received the CAR T-cell dose with dabrafenib and tra-
metinib without prior lymphodepletion.
We observed limited expansion or persistence of the CAR T 
cells in Patients 101, 102, and 203. Quantitative PCR measure-
ments of the CAR transgene in peripheral blood indicate that 
CAR T-cell numbers peaked around day 7, declined after day 14, 
and were undetectable by day 42 for Patients 101 and 102 although 
Patient 203 had very low levels of circulating CAR T cells at all 
time points from day 7 to day 42 (Figure 7b) . Fluorocytometric 
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detection of peripheral blood CAR T cells followed a similar time-
course, and serum cytokines also peaked at around day 7 postin-
fusion with a transient increase in IL-6 observed for all patients 
and an increase in IFNγ observed for Patient 102 (Figure 7a,c 
and Supplementary Figure S6b,c). The lympho-depleted Patient 
201 showed more marked expansion of CAR T cells after infusion 
with a 10–100-fold increase in transgene copy number detected 
at days 7 and 14, compared to Patients 101 and 102, and a later 
peak in IL-6 around day 28. However, CAR T-cell numbers in the 
peripheral blood still declined from day 14 to day 42 and were 
only detectable at low levels by month 4. This suggests that fluda-
rabine and cyclophosphamide conditioning improved expansion 
but did not dramatically improve persistence of GD2-iCAR-PBT 
cells in vivo. However, given that only one patient has received 
preconditioning in this study so far, we cannot draw definitive 
conclusions.
Compared to PBMC drawn at the same time from the same 
patient, peripheral blood CAR T cells had an inverted CD4:CD8 
ratio (Figure 7d), with CD8 T-cell frequency increased for all 
patients except Patient 201 (see Supplementary Figure S1b). 
Compared to the infused CAR T-cell product, which had a 
predominately effector-memory phenotype, the majority of 
peripheral blood CAR T cells had either an effector-memory or 
effector phenotype and also had upregulated expression of PD-1 
Figure 5 PD-1/PD-L1-dependent activation-induced cell death (AICD) after activation of GD2-iCAR T cells. (a) PD-L1 expression on thawed 
chimeric antigen receptor (CAR) T cells after stimulation in vitro. (b) Immune phenotype of CAR PD-L1+ and PD-L1- T cells at day 3 poststimulation. 
Immune phenotype defined as: Naive (CD45RA+CCR7+), effector memory (Tem; ––CD45RA–CCR7–), central memory (Tcm; –CD45RA–CCR7+),  effector 
–(CD45RA+CCR7–), activated (CD25+/CD69+), proliferating (CFSE low). (c) CAR T-cell viability after repetitive stimulation with LAN-1. (d) GD2+PD-L1- 
M238 tumor cell viability and (e) GD2++PD-L1- LAN-1 tumor cell viability and (f) GD2+PD-L1+ M238R tumor cell viability after stress-test assay with 
PD-L1 blockade (anti-PD-L1). Repetitive antigen stress-test assays and flow cytometry analyses were performed in duplicate. Representative data are 
shown for patient 101, and graphs display mean ± stanadard error of the mean. The gating strategy is shown in Supplementary Figure S5.
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and PD-L1 (Figure 7e,f and Supplementary Figure S6d,e). 
Circulating CD8+ CAR T cells had significantly higher PD-1 sur-
face expression compared to normal peripheral CD8+ T cells for 
both Patients 101 and 102, whereas for Patient 201 CD4+ CAR 
T cells had significantly higher PD-1 expression than normal 
peripheral CD4+ T cells. In the case of PD-L1, Patient 102 had 
significantly higher surface expression on both CD4+ and CD8+ 
CAR T cells compared to normal T cells at multiple time points 
following infusion. Significantly higher PD-L1 surface expression 
was also observed on CD4+ CAR T cells from Patient 101 and on 
CD8+ CAR T cells from Patient 203.
Lack of persistence may be related to activation induced cell 
death, as we observed in vitro, or may be due to a CAR-specific 
immune response mounted after infusion. To investigate this pos-
sibility, we assayed patient sera for human anti-mouse antibody 
IgG (HAMA) and patient PBMC for CAR-specific CTL response. 
No HAMA was detected at any time point postinfusion in Patients 
101 and 102, whereas Patient 201 had pre-existing HAMA that 
increased approximately fivefold by month 4 following CAR T-cell 
infusion (see Supplementary Figure S7a). Patient 203 had very low 
HAMA levels that did not increase over the 6-week time course. 
CTL responses were investigated using the protocol described by 
Lamers et al.8 to identify and expand CAR-specific clones within 
the peripheral blood. We compared PBMC stimulated with NT 
control T cells, GD2-iCAR T cells incorporating iCasp9, or GD2-
CAR T cells lacking iCasp9, to determine whether the GD2-CAR 
construct was immunogenic and whether the inclusion of iCaps9 
increased the immunogenicity of the CAR construct. We identi-
fied low levels of CAR-specific T cells in month 4 peripheral blood 
samples for Patient 101, at a frequency of 1–2% in the viable CD3+ 
Figure 6 Chimeric antigen receptor (CAR) cross-linking also induces activation-induced cell death. (a) Viability, (b) activation, (c) PD-1, and 
(d) PD-L1 expression after CAR cross-linking with 1A7 and secondary antibody (2°) of thawed CAR T cells and nontransduced (NT) controls. (e) GD2-
iCAR T-cell AICD in the presence of PD-1-, PD-L1-, or FAS-blocking antibodies after CAR cross-linking. Cross-linking assays and flow cytometry analyses 
were performed in duplicate. Representative data are shown for patient 101, and graphs display mean ± stanadard error of the mean. The gating 
strategy is shown in Supplementary Figure S5.
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population (see Supplementary Figure S7b,c). However, no sig-
nificant CAR-specificT-cell responses above 1% were detected in 
samples at other time points for Patient 101, or in any samples 
from Patient 102, and thus were considered below the limit of 
detection. Interestingly, the CAR-specific T-cell response at month 
4 was detected only in PBMC stimulated with irradiated T cells 
bearing the GD2-iCAR and not the GD2-CAR, which suggests 
that any T-cell response in these patients directed against epitopes 
within the iCasp9 molecule.
DISCUSSION
In the phase 1 CARPETS trial (ACTRN12613000198729), we 
are investigating adoptive transfer of third-generation GD2-
iCAR-PBT in patients with metastatic B-raf kinase (BRAF)-
mutant melanoma who concurrently receive dabrafenib with or 
without trametinib, and BRAF-wildtype melanoma who receive 
lymphodepleting therapy. The GD2-iCAR consists of CD3ζ, CD28, 
and OX40 signaling domains coupled to the 14g2a scFv31,32 and an 
iCasp9 suicide gene.33,34 The same technology is also currently on 
trial in neuroblastoma patients (GRAIN; NCT01822652).
The failure of adoptively transferred CAR T cells to persist and 
expand in patients strongly correlates with a lack of antitumor 
efficacy. There are several proposed theories for this lack of per-
sistence including exhaustion,22 AICD10,12 and immune-mediated 
deletion.8 In this paper, we have investigated whether any of these 
factors influence the survival of third-generation GD2-specific 
CAR T cells currently being tested in phase 1 clinical trials, which 
is particularly important given the inclusion in the CAR of regions 
reported to impact on CAR T-cell efficacy such as the 14g2a scFv 
and the IgG CH2–CH3 spacer, and we have also sought to better 
define the events occurring following antigen encounter by CAR 
T cells.
100
80
60
%
 o
f C
D3
+ 
T 
ce
lls
40
20
0
100
80
60
%
 o
f v
ia
bl
e 
CD
3+
 C
D8
+ 
T 
ce
lls
%
 o
f v
ia
bl
e 
CD
3+
 C
D8
+ 
T 
ce
lls
40
20
0
3,000 5
4
3
2
1
0
IgG
Control
2,000
1,000
250
Co
py
 n
um
be
r/p
er
 1
,0
00
 n
g 
gD
NA
%
 o
f C
D3
 T
 c
el
ls
200
150
100
50
0
0 7 14 21 28 35 42 49
Day Month 4 Month 8 Month 12
Patient 101
Patient 102
Patient 201
Patient 203
Patient 101
PBMC CD8+IFNγ
Normal PBMC
CAR T cell
Normal PBMC
CAR T cell
Normal PBMC
CAR T cell
Normal PBMC
CAR T cell
nd nd
TNF
IL-10
IL-6
IL-4
IL-2
PBMC CD4+
CAR CD8+
CAR CD4+
Patient 102
Patient 201
Patient 203
73 146 219 292 365 0 7 14 21 28 35 42 49
Day
0 7 14 21 28 35 42
Day
0 7 14 28 42
Day
0 7 14 28 42
Day
0 7 14 28 42
Day
nd
0 7 14 28 42
Day
nd
0 7 14 28 42
Day
Serum cytokine150
125
100
75
pg
/m
l 20
15
10
5
0
CD8 and CD4 T cells
Niave CD8 T cells Effector memory CD8 T cells
Central memory CD8 T cells Effector CD8 T cells
Pre-infusion
Pre-infusion
Pre-infusion
50
(i) (ii)
(iii) (iv)
40
30
20
10
0
%
 o
f v
ia
bl
e 
CD
3+
 C
D8
+ 
T 
ce
lls 50
40
30
20
10
0 %
 o
f v
ia
bl
e 
CD
3+
 C
D8
+ 
T 
ce
lls 100
80
60
40
20
0
Pre-infusion
Pre-infusion
*
**
6 hrs 24 hrs
CAR T cells-QPCR CAR T cells-FLOW
Month 4 Month 8 Month 12
73 146 219 292 365
a b
c d
e
1144 www.moleculartherapy.org vol. 24 no. 6 jun. 2016
© The American Society of Gene & Cell Therapy
Activation-induced Cell Death in GD2-specific CAR T Cells
First, we tested GD2-iCAR T cells for evidence of the func-
tional exhaustion resulting from the tonic CAR-signaling that 
has been reported by others.22 We found that PD-1, LAG-3, and 
TIM-3 were not constitutively expressed, but that PD-1 and 
LAG-3 were upregulated transiently during CAR T-cell stimula-
tion. Initial stimulation of CAR T cells resulted in potent cyto-
kine secretion, which was diminished after restimulation, and 
we observed recovery of IFNγ and TNFα, but not IL-2 produc-
tion when we blocked PD-1 using pembrolizumab mAb. Loss of 
IL-2 has been identified as one of the early steps leading to T-cell 
exhaustion and so may indicate a late-stage effector phenotype.35 
A reduction in cytokine secretion was also observed after restimu-
lation of NT controls, indicating that CAR signaling was not solely 
responsible for the loss of T-cell function. Thus although GD2-
iCAR T  cells lose some effector functions during longer-term 
culture and restimulation, the third-generation CAR does not 
seem to produce the same high levels of tonic CAR signaling and 
functional exhaustion reported for the GD2-specific, second-gen-
eration CD28-CD3ζ CAR36 perhaps because of OX40 coexpres-
sion in the third-generation construct. Nevertheless, these results 
do highlight the importance of rigorous multifunctional analysis 
of CAR T cells during product development, because immedi-
ate effector functions such as target cell lysis and IFNγ secretion 
observed in vitro may not be an accurate indicator of CAR T-cell 
efficacy in the clinic.
GD2-iCAR signaling resulted in different kinetics for down-
stream signaling events, with more rapid calcium flux and sig-
naling molecule phosphorylation, and third-generation CAR 
of this kind have been previously reported to be more prone to 
AICD due to the potent stimulation induced.17 Higher basal levels 
of phosphorylated molecules in resting cells suggests that CAR 
T cells do have a higher activation state before antigen encoun-
ter. Importantly, NT T cells expanded under the same conditions 
also displayed higher basal levels of signaling molecule phos-
phorylation and active caspase 3 than unmanipulated T cells from 
PBMC samples. Thus, we could identify some changes in activa-
tion potential and signaling that were due to the effector mem-
ory phenotypes generated by ex vivo cell-expansion conditions, 
as opposed to the intrinsic properties of the third-generation 
CAR. A central memory or naive/stem-like memory phenotype 
is associated with superior T-cell persistence whereas an effec-
tor memory phenotype has been associated with poor antitumor 
responses.6,7,37 Consequently, we hypothesize that improvements 
in ex vivo activation and expansion conditions that promote 
central memory or stem-like phenotypes may be used to correct 
some defects in CAR T-cell function observed in this paper. For 
example, parameters influencing optimal T-cell therapy product 
development such as cytokine supplementation, stimulation con-
ditions and transduction of defined T-cell subsets have previously 
been investigated.37–39
Our second aim was to investigate whether GD2-iCAR T cells 
experience activation-induced cell death, as has been reported by 
others.10 Using an antigen “stress-test” and receptor cross-linking 
assays, we found that GD2-iCAR T cells had reduced viability after 
antigen encounter, and lost the ability to kill GD2-specific tumor 
cell lines.AICD has long been noted in T cells following stimula-
tion.13,15 The iCasp9 molecule has not previously been reported 
to undergo spontaneous dimerization, however we investigated 
Figure 7 Chimeric antigen receptor (CAR) T-cell persistence and immune phenotype in patients receiving third-generation GD2-specific 
CAR T cells for the treatment of V600 BRAF-mutant metastatic melanoma. (a) Flow cytometry using 1A7 to detect GD2-iCAR-expressing T cells 
in peripheral blood. (b) Quantitative polymerase chain reaction (QPCR) to detect GD2-iCAR transgene-positive cells in peripheral blood. (c) Patient 
102 serum cytokine levels. (d) Patient 102 CD4 and CD8 CAR T-cell subsets for peripheral blood mononuclear cells, the GD2-iCAR T-cell product 
and circulating GD2-iCAR T cells detected from day 7 postadministration. (e) Patient 102 CD8+ T-cell immune phenotype and (f) PD1/PD-L1 expres-
sion on peripheral blood normal T cells and 1A7+ GD2-iCAR T cells. Experiments were performed in duplicate (flow cytometry) or triplicate (QPCR), 
with graphs displaying mean ± standard error of the mean. Gating strategy and data for Patients 101, 201 and 203 are shown in Supplementary 
Figure S6.
Normal PBMC
CAR T cell Normal PBMCCAR T cell
Normal PBMC
CAR T cell
Normal PBMC
CAR T cell
nd
0 7 14 28 42
Day
nd
0 7 14 28 42
Day
nd
0 7 14 28 42
Day
nd
0 7 14 28 42
Day
PD-1+ CD8 T cells PD-1+ CD4 T cells
PD-L1+ CD8 T cells PD-L1+ CD4 T cells
Pre-infusion
Pre-infusion
(i) (ii)
(iii) (iv)
%
 o
f v
ia
bl
e 
CD
3+
 C
D8
+ 
T 
ce
lls 10
8
6
4
2
0 %
 o
f v
ia
bl
e 
CD
3+
 C
D4
+ 
T 
ce
lls 10
8
6
4
2
0
%
 o
f v
ia
bl
e 
CD
3+
 C
D8
+ 
T 
ce
lls 30
20
10
0 %
 o
f v
ia
bl
e 
CD
3+
 C
D4
+ 
T 
ce
lls 30
20
10
0
Pre-infusion
Pre-infusion
**
**
*
*
f
Molecular Therapy vol. 24 no. 6 jun. 2016 1145
© The American Society of Gene & Cell Therapy
Activation-induced Cell Death in GD2-specific CAR T Cells
whether this element contributed to AICD. We found that CAR 
T  cells transduced with an iCasp9-negative vector experienced 
the same level of rapid caspase 3 activation (<12 hours stimula-
tion) and AICD and this was also observed in NT controls stimu-
lated via CD3 and CD28 receptors, albeit in a lower percentage 
of T  cells. AICD could also be induced in PBMC although the 
stimulation over a longer time period (>24 hours) was required 
to observe the effect. Thus, the expression of the third-generation 
CAR leads to a heightened activation state, which contributes to 
AICD after repeated antigen stimulation. However, this phenome-
non is also seen to some extent in NT T cells with effector memory 
phenotype and is not caused solely by the CAR-intrinsic elements 
such as intracellular signaling molecules or iCasp9.
During these investigations, we have found that PD-1 block-
ade restored CAR T-cell cytokine production and promoted both 
GD2-iCAR T-cell survival and killing of GD2+ PD-L1+ tumor cells 
during stress-test assays. Furthermore, we found that activated 
CAR T cells upregulated the PD-1 ligands, PD-L1 and PD-L2, 
and the PD-1 receptor-ligand interactions between GD2-iCAR 
T cells were sufficient to induce AICD in the absence of tumor 
cells. To determine the ligand responsible for PD-1-dependent 
AICD, we blocked PD-L1 with blocking antibody and performed 
siRNA knockdown of PD-1 and PD-L1. This revealed that PD-L1 
immune blockade inhibited AICD of CAR T cells, particularly in 
the presence of receptor cross-linking, while conversely PD-L1 
knockdown by siRNA reduced CAR T-cell viability and PD-L2 
blockade had no significant effect.
PD-1 and ligands, PD-L1 and PD-L2, modulate immune 
responses via inhibition of proliferation and cytokine secretion,40,41 
blockade of survival gene expression,42 promotion of Treg differ-
entiation,43 and induction of cell death.44,45 PD-L1 in particular has 
complex roles in both immune activation and suppression that are 
still being elucidated. PD-L1 signaling via PD-1 causes inhibition 
or deletion of activated PD-1+ T cells30,46 whereas signaling via 
CD80 enables costimulation of naive T cells.47 In addition to this, 
PD-L1 reportedly mediates reverse signaling within PD-L1+ T cells 
and protects them from cell death. PD-L1-deficient T cells express 
lower levels of antiapoptotic molecules and are more susceptible 
to apoptosis during the contraction phase after antigen-specific 
expansion.29,48 Early blockade of PD-L1 reportedly enhances 
antigen-specific T-cell expansion, while late blockade reduces the 
survival of effector T cells.29 Beneficial PD-L1 reverse signaling 
has also been identified in the survival of PD-L1+ tumor cells and 
renders these cells resistant to CTL-mediated and FAS-mediated 
killing.48 These findings support our observations that PD-L1 
blockade improved T-cell survival at early time points postactiva-
tion, while conversely PD-L1 knockdown led to reduced survival 
of CAR T cells. Thus, we hypothesize that PD-L1 signaling may 
induce AICD in PD-1+ CAR T cells, but also promote survival 
of PD-L1+ CAR T cells via reverse signaling. It is important to 
note that PD-1/PD-L1 interactions are likely just one mechanism 
that contributes to AICD and only the subset of T cells expressing 
PD-1 will benefit from PD-1 blockade. We also found that FAS, 
another molecule identified in AICD, was also highly expressed 
on GD2-iCAR T cells and FASL was upregulated during stimula-
tion. Blockade of FAS also promoted CAR T-cell survival, albeit at 
the expense of some CAR T-cell cytotoxic function. Therefore, we 
have identified a novel role for PD-1/PD-L1 interactions in AICD 
of CAR T cells, in addition to the FAS/FASL interactions previ-
ously identified by others10
One limitation of this study is that we lacked first- or second-
generation GD2-CAR constructs, or constructs with different 
GD2-affinities, to compare to our third-generation CAR. It would 
be interesting to investigate to what extent re-engineering of CAR 
constructs would influence AICD and the PD-1/PD-L1 signaling 
axis. We hypothesize that the strength of CAR-mediated activa-
tion determines CAR T-cell deletion versus persistence, and may 
well play a role in the memory phenotype and functional potential 
of surviving T cells. In this GD2-CAR, it is possible that removing 
the OX40 signaling domain entirely,18 replacing it with the 41BB 
signaling domain24 or 41BB ligand49 as reported by others, may 
reduce or prevent AICD and/or PD-1-mediated suppression.
We have applied our understanding of our in vitro results to 
an analysis of peripheral blood samples derived from patients 
enrolled in the ongoing CARPETS clinical trial. The limited num-
ber of patients enrolled thus far, means the results presented are 
descriptive and cannot be used to form definitive conclusions. 
However, we identified upregulated expression of both PD-1 
and PD-L1 on a subset of peripheral-blood GD2-iCAR T cells, a 
detectable GD2-iCAR+ population declined in all patients beyond 
day 28 postinfusion, and failed to persist in Patients 101 and 
102, suggesting that mechanisms of CART-cell deletion we have 
identified in vitro may also be at play in vivo. Deletion may occur 
after GD2 antigen encounter or from nonantigen specific activa-
tion, for example, after engagement of the IgG CH2–CH3 spacer 
region with FcyR-bearing immune cells,10,12 and this requires fur-
ther investigation. However, we propose that the timing of peak 
serum cytokines in CARPETS patients (days 7–28) may indicate 
antigen encounter because they occur at a similar time (~day 
17) to the peaks of serum IFNy and IL-6 observed in leukemia 
patients treated with CD19-specific CAR T-cells,1 albeit at much 
lower concentrations.
Another hypothesis for lack of persistence is that a CAR 
T-cell-specific immune response targets the mouse-derived 14g2a 
scFv, the retroviral sequences, or the modified iCasp9 gene and 
cause immune-mediated deletion of CAR T cells. However, the 
low level and delayed timing of CAR-specific T-cell responses 
detected probably does not account for the reduction in detectable 
circulating CAR T cells by day 28 postinfusion. Furthermore, an 
increase in titer of (pre-existing) HAMA was detected in only one 
patient postinfusion, and this patient (201) is currently the only 
patient with detectable CAR T cells at month 4. Hence, we pro-
pose that early CAR T-cell deletion is more likely related to AICD 
than to postinfusion anti-CAR transgene immune responses.
The lack of persistence may be overcome with preinfusion 
lymphodepleting chemotherapy, which is known to have multi-
ple effects on both tumor and immune environments, including 
the removal of suppressive cells and the provision of homeostatic 
cytokines to newly infused cells.50 The third patient enrolled in 
the CARPETS trial (Patient 201) received fludarabine and cyclo-
phosphamide (FluCy) conditioning as part of the CARPETS pro-
tocol and we immediately observed increased expansion of CAR 
T cells, however CAR T cells then declined from day 14. These 
data indicate that although the lymphodepleting chemotherapy 
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supported GD2-iCAR T-cell expansion, the expanded population 
of adoptively transferred cells did not persist, perhaps because of 
active T-cell deletion. However at this stage, our results can only 
be descriptive until more patients are enrolled to the study.
Mounting clinical evidence indicates that pre-existing T-cell 
immunity is required for therapeutically effective PD-1 and PD-L1 
blockade.20,36 CAR T cells may provide a source of primed immune 
effectors when endogenous responses are insufficient. Here, we 
have identified important roles for PD-1 interactions in the sup-
pression of CAR T-cell effector functions as well as a novel role in 
CAR T-cell AICD, and these findings complement other preclini-
cal studies.21 In a recent protocol amendment for the GRAIN trial 
of GD2-specific CAR T cells in neuroblastoma patients, concur-
rent treatment with anti-PD-1 mAb has been allowed. The cur-
rent study therefore further supports the rationale for combining 
anti-PD-1 mAb and CAR T-cell therapy, which we hypothesize 
may also benefit patients with tumors lacking PD-L1 expression if 
the CAR T cells express PD-L1. We therefore propose to incorpo-
rate anti-PD-1 mAb combination therapy into the next cohort of 
patients enrolled in the CARPETS clinical trial.
MATERIALS AND METHODS
Human subjects. Blood samples were obtained from patients with mel-
anoma who provided written informed consent. The Royal Adelaide 
Hospital Human Research Ethics Committee approved the research pro-
tocols for the CARPETS trial (ACTRN12613000198729). In addition to 
the initial blood donation, patients enrolled in the CARPETS trial donated 
blood for analysis of persistence and immune phenotyping at days 0, 7, 
14, 28, and 42 postadministration of autologous GD2-specific CAR T cells 
(GD2-iCAR PBT). Two metastatic melanoma patients (101 and 102), who 
did not have prior lymphodepletion, received the lowest GD2-iCAR-PBT 
dose level of 10 million cells/m2. Each patient had a tumor containing a 
V600 BRAF mutation and so received concurrent dabrafenib at the time 
of PBMC procurement and during the 6-week study evaluation period 
postinfusion. After a protocol amendment to allow concurrent treatment 
with dabrafenib and trametinib for patients with V600 BRAF mutant 
melanoma and lymphodepleting chemotherapy for patients with V600 
BRAF mutation-negative melanoma, patients were enrolled at the second 
dose level. A third metastatic melanoma patient (201) had a V600 BRAF 
mutation-negative melanoma and had not had previous systemic therapy 
for melanoma. This patient received the second dose level of 20 million 
GD2-iCAR-PBT cells/m2 on day 0 after lymphodepletion with fludarabine 
30 mg/m2 on days −4, −3, and −2 and IV cyclophosphamide 500 mg/m2 on 
days −4 and −3. A fourth patient (203) with metastatic V600 BRAF mela-
noma received the second dose level of 20 million GD2-iCAR-PBT cells/
m2 concurrent with dabrafenib and trametinib.
Cell lines and patient-derived primary cells. LAN-1 (neuroblastoma cell 
line), M238, M238R1, and SK-Mel-28 (melanoma cell lines) were main-
tained in RPMI supplemented with 10% FBS, 1% L-Glutamine, and 1% 
Penicillin/Gentamicin (IDL, Adelaide, Australia). M238 and M238R1 cell 
lines were gratefully received from Roger Lo (UCLA, Los Angeles, CA). 
To generate GD2-iCAR PBT, patient PBMC were purified by density 
gradient separation, activated for 3 days with anti-CD3 and anti-CD28 
(Miltenyi Biotec, Sydney, Australia), transduced with the GD2-iCAR ret-
roviral vector SFG.iCasp9.2A.14g2a.CD28.OX40.zeta supernatant (CAGT, 
BCM, Houston, TX), and then expanded for 10–14 days in IL-7 and IL-15 
(Miltenyi Biotec, Sydney, Australia) and cryopreserved before use, as 
described previously.23 Nontransduced (NT) controls were activated and 
cultured in the same manner, but without retrovirus. Patient PBMC pre- 
and postadministration were purified and cryopreserved before analysis, 
as described previously. All cells were thawed and rested overnight before 
analysis in in  vitro assays.
Flow cytometry. Cells were analyzed on BD FACSCanto II (BD Biosciences, 
North Ryde, Australia) and FlowJo Software (TreeStar, Ashland, OR). Isotype 
and FMO controls were used in each assay to establish negative gates and 
cells were incubated with Human Fc-block (BD Biosciences, North Ryde, 
Australia) for 5 minutes before staining. All gating strategies and represen-
tative data sets are shown in Supplementary Figures S1–S6. Staining was 
performed as described previously,27 with 1A7 (anti-idiotypic mAb for GD2-
iCAR purified in house) and PE-conjugated secondary (BD Biosciences) 
used to detect CAR+ T cells in all instances. To detect cytokine secretion, 
cytokine bead arrays were performed using a BD Human Th1/Th2 Cytokine 
Assay Kit II according to the manufacturer’s instructions (BD Biosciences). 
For proliferation assays, cells were stained with 1.5 µmol/l Cell Trace Violet 
(Life Technologies, Scoresby, Australia) before stimulation. For ratiomet-
ric calcium flux detection, CAR T cells were stained with 4 μmol/l Fluo-4 
AM (Molecular Probes, Eugene, OR), 10 μg/ml Fura Red AM (Molecular 
Probes), and 0.02% Pluronic F-127 (AAT Bioquest, Sunnyvale, CA) as 
described by others. Cell samples were recorded for 30 seconds to establish 
a baseline and then anti-CAR (10 μg/ml), anti-CD3 (10 μg/ml), anti-CD28 
(10 μg/ml) or cross-linking secondary antibodies (10 μg/ml) were added, 
and recordings made for a further 270 seconds. Ionomycin was used as a 
positive control, and some cells were prestained with primary antibodies for 
30 minutes before adding crosslinking secondary antibody. For signaling 
molecule phosporylation detection, anti-pERK1/2-FITC, anti-pAKT-bv421, 
or anti-pSTAT6-FITC anti-pSTAT5-bv421 (BD Biosciences) were used. For 
viability and activation analyses, cells were stained with Annexin V-FITC, 
CD69-Pecy7, CD25-APC-Cy7, and DAPI (Sigma Aldrich, Castle Hill, 
Australia). GD2 expression on tumor cells was detected with anti-GD2-APC 
(14g2a clone, BD Biosciences).
In vitro functional assays. For stimulation assays, cells were stimulated with 
plate-bound 1 µg/ml anti-CD3/CD28 (Miltenyi Biotech) or 2 µg/ml 1A7 for 
3 days, cells and supernatants were collected for analysis by flow cytometry, 
and remaining cells were transferred to uncoated wells with fresh media. For 
restimulation, cells were stimulated for 3 days, rested for 4 days, and then 
restimulated for 3 days as above. For crosslinking assays, cells were cultured 
with either 1 µg/ml soluble 1A7 or 1 µg/ml soluble 1A7 or 10 µg/ml soluble 
antimouse IgG secondary. For coculture “stress-test” assays, tumor and CAR 
T cells were cultured at a 1:1 ratio, as described by others.10 Every 24 hours, 
CAR T cells were removed and replated onto fresh tumor cells at a 1:1 ratio. 
Remaining tumor cells and a sample of CAR T cells were retained at each 
24-hour time point for analysis of viability by flow cytometry. Cytotoxicity 
assays were performed as described previously,27 with GD2-iCAR PBT 
cocultured with 51Cr-labeled LAN-1 neuroblastoma, M238, or M238R1 
melanoma cells, and autologous PHA-blasts or SK-Mel-28 melanoma cells 
(as negative controls) for 6 hours before 51Cr-release was analyzed.
Detection of CAR-specific immune responses. Human antimouse antibody 
was assayed using patient serum collected pre and post CART-cell infu-
sion using a HAMA ELISA kit (Biolegend, San Diego, CA) according to the 
manufacturer’s instructions. CAR-specific immune responses were assayed 
as described by Lamers et al. Briefly, PBMC from preadministration, day 28, 
day 42, and month 4 timepoints were cultured with autologous, irradiated 
CAR T cells or NT control T cells as feeder cells at a 4:1 ratio. New feeder 
cells were added every 7 days for 4 weeks. We used CD107a (BD Biosciences) 
staining as a marker of degranulation to assess responses. Responses were 
considered negative when the flow cytometry assay yielded a net %CD107a+ 
population of <1%, based on the background observed for PBMC stimulated 
with NT control T cells.
Blockade or knockdown of PD-1, PD-L1, or FAS. In selected assays, 20 µg/ml 
pembrolizumab (anti-PD-1), 10 µg/ml anti-PD-L1-neutralizing antibody 
MIH1 10 µg/ml anti-PD-L2 neutralizing antibody MIH18 (eBioscience, 
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San  Diego, CA),51 and 10 µg/ml anti-FAS-neutralizing antibody ZB452 
(Millipore, Billercia, MA), were included from the initiation of culture. 
siRNA designed against the PD-L1, PD-1, and FAS human DNA sequence 
(Sigma Aldrich, Castle Hill, Australia) were introduced into cells by elec-
troporation and knock down of target molecules was confirmed by flow 
cytometry. Cells electroporated with scrambled-siRNA were used as a nega-
tive control.
Statistical analyses. Data were analyzed using GraphPad Prism Version 6.0d 
(GraphPad Software, La Jolla, CA). Data were analyzed by one-way analysis 
of variance (for single variable data) or two-way analysis of variance (for two 
variable data) and Bonferroni multiple comparison posttests. Significance is 
represented on graphs as *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
SUPPLEMENTARY MATERIAL
Figure S1. Gating strategy for activation and exhaustion markers.
Figure S2. Investigating CAR T-cell function during primary and 
repeated stimulation.
Figure S3. Intracellular signalling after stimulation of CAR T cells.
Figure S4. Repeated antigen stimulation assay.
Figure S5. Expression of PD-L1, FAS and FASL on CAR T cells, and 
effects of blocking these molecules during stimulation.
Figure S6. GD2-iCAR PBT persistence and immune phenotype in 
patients.
Figure S7. CAR-specific immune responses in patients postCAR T-cell 
infusion.
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